Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 3
Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer
Panelists explore emerging combination therapies in maintenance treatment for advanced ovarian cancer, including rucaparib + nivolumab; atezolizumab + bevacizumab; and olaparib + cediranib, also discussing how these strategies fit into the current treatment paradigm and in which patient populations they may be considered.
Video Player is loading.
Video content above is prompted by the following:
- Typically, how long do you keep patients on PARP inhibitors in first-line maintenance? What about second-line maintenance?
